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Abstract
Parkinson’s disease dementia is a critical stage of the disease because that has a 
negative impact on the quality of life and functional independence in activities daily 
living. How the cognition progress to dementia is a key to be explored. The cognitive 
impairment shows two profiles: cortical (memory encoding, visuospatial abilities, 
and language) and subcortical, with a dysexecutive syndrome that includes deficits 
in recognition memory, attention processes, and visual perception as well as visual 
hallucinations and cognitive fluctuations. Behavioral problems such as apathy, 
anxiety, depression, and impulse control disorders take a significant part in the loss 
of autonomy and progression of the disease. To detect the risk of Parkinson’s disease 
dementia development, the integral evaluation of patients in all stages of the disease 
should consider the interplay of genetic and epigenetic factors, motor subtypes, 
and non-motor symptoms (NMS) in order to implement different therapeutics and 
supportive strategies when they are likely to have efficacy.
Keywords: Parkinson’s disease, biomarkers, cognitive impairment, dementia, 
personalized medicine
1. Introduction
Parkinson’s disease (PD) is the second most common neurodegenerative disease 
worldwide after Alzheimer’s disease (AD). Nowadays, PD is considered a pan-
demic and the projection in the next years exhibited a fast growing of the disease. 
Estimating the high prevalence of cognitive impairment in the course of the disease, 
we must encourage the research and increase of health policies to reduce the impact 
of quality of life and its costs to the health care system.
There is a new and necessary perspective to understand the multicausality of the 
neurodegenerative diseases that most affect the population. By making available 
clinical, biological, genetic, and functional brain imaging markers in an individual-
centered clinical practice, it will allow an approach to the principle of precision 
medicine. This can contribute to optimization of the selection of pharmacological 
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management or non-pharmacological strategies of symptomatic or preventive 
treatment for cognitive impairment even at early stages of PD. Therefore, identify-
ing patients with potential risk of dementia could guarantee proper treatment and 
strategies to support the functional impact. We are beginning to understand the 
conceptual and therapeutic overlap by reclassifying the shared pathogenic mecha-
nisms and therapeutic targets.
The integral and multidisciplinary approach of the motor symptoms (MS) and 
non-motor symptoms (NMS) through the natural history of the disease allows to 
provide a specific treatment and improve the quality of life.
2. Epidemiology
PD produces a considerable epidemiological burden associated with high rates 
of disability [1]. Due to the world population’s aging and other unclear factors, PD 
prevalence and incidence are dramatically increasing, even surpassing the growth 
of AD [2]. Epidemiological data on PD are highly variable across countries. These 
differences can be explained by the variability in the diagnostic criteria, changes 
in population age distribution and the access to health care services, including the 
opportunity to consult with trained doctors and specialists [3–5].
According to the Global Burden of Disease study, 6.2 million patients live with 
PD and this frequency will double by 2040. In 2015, the country with the highest 
age-adjusted PD prevalence was China with 136.34 cases per 100,000 inhabitants 
(CI 11.56–165.55) and the lowest was Tanzania with 72.19 (CI 59.86–87.82) [5, 6]. 
Since 1990 until 2017, PD had a small but significant increase in the age-standard-
ized rates of incidence (21.9% [UI, 11.2–14.6%]), prevalence (16.2% [UI, 2.7–31%]), 
mortality (33.1% [UI, −4.6–41.7%]), and DALY (24.8% [UI, −5.2–32.9%]) [6].
People living with PD often have other comorbidities, which contribute to their 
prognosis related to the quality of life, and mortality [7]. Xin Wang et al., in a large 
retrospective study in China, collected and quantified PD comorbidity burden by 
the Elixhauser Comorbidity Index (ECI) and Charlson Comorbidity Index (CCI). 
The comorbidity spectrum differed between PD and parkinsonism patients. The 
most frequent comorbidities for the PD patients were cerebrovascular disease 
(42.53%), hypertension (33.17%), diabetes (10.60%), chronic pulmonary disease 
(6.98%), and paralysis (5.53%). For the parkinsonism patients, cerebrovascular 
disease (53.22%), hypertension (39.00%), diabetes (11.66%), paralysis (11.06%), 
and dementia (7.05%) were more common. Parkinsonism patients more frequently 
had cerebrovascular disease, dementia, paralysis, hypertension, weight loss, and 
drug abuse than patients with PD, but they had a lower prevalence of solid tumor 
without metastasis and mild liver disease [8, 9].
Dementia occurs as part of the neurodegenerative process, which directly leads to 
a decrease in the quality of life of PD and parkinsonism patients. A systematic review 
showed that the prevalence of dementia in patients with PD (PDD) ranges from 
17.4 to 31.5%, with an average of 24.5%, which is higher than that in our cohort. The 
prevalence of dementia in our Colombian cohort is 4.9% for all patients and 6.9% for 
patients aged 65 years and older, which is considerably higher than the prevalence of 
5.14% observed in the general Chinese population aged 65 years and older [4, 10].
In addition, a recent meta-analysis shows that the pooled prevalence of mild cog-
nitive impairment associated with PD was 40% more frequent for multiple domain 
subtype. Currently, it is considered that mild cognitive impairment is a risk factor 
for the development of dementia [11, 12]. The prevalence of mild cognitive impair-
ment (PD-MCI) in patients with PD is in a range of 20–50%, and these patients are at 
high risk of developing dementia [13]. In a recent review on cognitive impairment in 
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patients with PD, it was reported that in the long term the progression of the disease 
can generate dementia in more than 75% of patients, which is closely linked to the 
disease duration of 10 years or more [14]. Finally, PDD and PC-MCI have a great 
impact on quality of life in patients, and their caregivers [15]. Thus, it is necessary to 
understand deeply and broadly the motor and non-motor spectrum of the disease in 
order to find novel therapeutics and preventive approaches.
3. Pathophysiology
The clinical and pathological changes associated with PPD are complex. The 
following section summarizes the genetic and histological changes associated with 
the pathophysiology of dementia in these patients.
3.1 Genetics of PD dementia
Although the genetic risk factors for PD have been investigated, much less is 
known about the genetic factors associated with the development of dementia in 
PD. According to some studies, the prevalence of PDD is lower in patients with 
genetic PD. However, this will depend on the gene variant and other comorbidities 
that predispose the development of cognitive disorders. Some of the most important 
genes are discussed below:
• PARK1: patients with duplication or triplication of alpha-synuclein gene 
(α-Syn) have more severe motor progression and worse cognitive prognosis 
[16] compared to those without the mutation. Although the evidence suggests 
that the higher the number of replications, the lower the age of onset of cogni-
tive impairment. Of all genes, this seems to be the most related to dementia. 
More studies are needed to confirm these findings [17].
• PARK2: according to some case series, mutations in PARK2 do not seem to 
cause cognitive decline [18].
• PARK14: PLA2G6 mutation could show heterogeneous phenotype including 
dementia.
• DJ-1: due to its low prevalence, there is no clear relationship between DJ-1 
and a particular PD cognitive phenotype. There are some reports of dementia 
within the clinical spectrum of DJ-1 mutations. In a large population-based 
survey, there was no evidence for an increased risk of dementia in carriers of 
DJ-1 deletion [19].
• LRRK-2: there is conflicting evidence between this mutation and the develop-
ment of dementia. In a large Algerian cohort of 106 patients (34 mutated), 
there was no relationship between the presence of mutations and cognitive 
abnormalities [20, 21].
• PINK1: due to its low prevalence, there is conflictive evidence on the relation 
between PINK1 and PD dementia or cognitive decline [22].
• APOE4: the presence of Aβ plaques and neurofibrillary tau tangles (NFT) 
are characteristic of cognitive impairment in AD. But, in PD patients, there-
fore, the APOE ε4 genotype is an additional risk factor to converse to PDD. 
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Although, some large cohort studies suggest there is no increased risk for 
developing dementia in carriers [23].
• GBA (glucocerebrosidase): this gene encodes a lysosomal membrane protein 
that cleaves the beta-glycosidic linkage of glycosylceramide, an intermediate 
in glycolipid metabolism [24]. Some studies suggest worse cognitive perfor-
mance in patients with mutations in this gene. Even in some cohorts, it has 
been considered an independent risk factor for the development of dementia. 
Mutations in glucocerebrosidase are a major genetic risk factor for PD and 
increase susceptibility to dementia in a Flanders-Belgian cohort [25].
3.2 Histological changes in patients with PD dementia
Genetic and environmental factors lead to protein misfolding, aggregation, and 
finally, the neural loss that is reflected in histological changes as mentioned below.
The pathologic findings for PDD include Lewy bodies (LBs), AD pathology, 
and cerebrovascular disease, among others. Apparently, the inclusions type and the 
brain localization influence the severity and type of cognitive impairment. LBs and 
Lewy related pathology (LRP: Lewy neurites) localized in neocortex and limbic 
areas are related to the risk of suffering dementia with a rapid progression and 
lower scores in all cognitive domains [26]. On the other hand, limbic distribution 
is associated with visuospatial skills impairment [27]. LB densities in the temporal 
lobe were significantly higher in cases with PDD, compared to PD without demen-
tia [28]. Furthermore, concomitant aggregation of b-amyloid (AD pathology) 
with LRP is associated with PDD. There is evidence in cell models that α-synuclein 
contributes to deposition of tau and b-amyloid, leading to a summative effect over 
the risk of PDD [29, 30].
The association of PDD and small vessel disease and cerebral amyloid angiopa-
thy remains elusive because these are also common findings in brains of elderly 
people [26].
4. Biomarkers of Parkinson’s disease dementia
Recent research is focused on the study of molecules or biomarkers related to the 
pathophysiological mechanisms of PD that can contribute in clinical practice to the 
diagnosis, prognosis, and monitoring of the progression of neurological diseases.
The most promising results have been obtained from neurofilament light chain 
protein (NFL), α-synuclein species, lysosomal enzyme activities, and classic AD 
biomarkers such as amyloid beta peptide 1–42 (Aβ42) and tau protein. An impor-
tant innovation for diagnostic is the identification of forms of α-synuclein prone to 
aggregation in early stages of PD [31]. Furthermore, the highest diagnostic accura-
cies to identify PD patients have been obtained from the combination of different 
biomarkers (Figure 1) [32]. However, these studies require further validation for 
clinical practice [33–35].
4.1 Cerebrospinal fluid and serum
Prediction of cognitive decline and progression to dementia in PD patients 
could be a promising tool in clinical practice. Some biomarkers used for AD in 
cerebrospinal fluid (CSF) have shown that low concentrations of Aβ42 in CSF are 
associated with worse cognitive scores and could predict cognitive impairment in 
patients with PD [36, 37].
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The performance and prognostic value of CSF Aβ42 improved when combined 
with other biomarkers of CSF. CSF Aβ42 levels <626 ng/L was associated with a 
hazard ratio (HR) of 2.8 (95% CI 1.4 to 5.8) for the development of dementia within 
5–9 years of follow-up. When the ratio of CSF NFL, FABP3, and Aβ42 is more than 
2.1, the HR values increased to 11.8 (95% CI 3.3–42.1) [38]. In addition, if the clini-
cal characteristics are analyzed with CSF Aβ42 levels, its prognostic value is further 
improved [39]. Thus, it has also been determined that low Aβ42 values could 
predict early psychosis in PD patients within 3–4 years of follow-up [40].
Both, total α-synuclein and homocysteine (Hcy) in CSF have shown contradic-
tory results as a predictor of cognitive impairment [31, 32, 41, 42]. Some neuroin-
flammatory reaction molecules such as interleukin 8 (IL-8) and C-reactive protein 
(CRP) levels in CSF are related to decreased MOCA scores in PD patients and PDD 
patients, respectively [43–45].
It has recently been determined that the blood neurofilament (NFL) can dis-
criminate between (PD) and atypical parkinsonian disorders (APD) with the same 
precision as in CSF, which would facilitate its use in the differential diagnosis of 
parkinsonian disorders, and would also allow to correlate the severity and progres-
sion of the motor and cognitive functions of PD [46].
Progression in motor disability in PD patients was associated with α-synuclein 
species concentrations [31]. Both the combination of ratio of phosphorylated tau to 
Aβ42 and CSF total tau have been found to have a correlation with a faster decline 
of performance in total unified Parkinson’s disease rating scale (MDS-UPDRS) over 
time. Tau pathology, as assessed by CSF phosphorylated tau, seems to have a role in 
accelerating motor progression [47]. Some studies suggested that there is a posi-
tive correlation between DJ-1, advanced oxidation protein products (AOPP), and 
8-OHdG levels, and a greater severity of the disease [32, 42, 48–50].
4.2 Neuroimaging
Advances in neuroimaging allow the identification of non-invasive biomark-
ers to confirm the diagnosis and possibly know the severity of the disease and also 
determine the functional prognosis. The Braak progression model does not respond 
precisely to the behavior of the clinical profiles or to the progression of parkinson-
ism in a real scenario, where epigenetic variables will be related to the evidence of 
Figure 1. 
Main biomarkers of PD. Figure 1 summarizes the serum, imaging, digital evaluation, and genetic and clinical 
biomarkers associated with the pathophysiology and course of dementia in Parkinson’s disease. TNF: tumor 
necrosis factor; CRP: C reactive protein; α-Syn: α-synuclein; UCH-L1: ubiquitin C-terminal hydrolase-L1; 
AB42: amyloid β peptide 1–42; NFL: neurofilament light chain; FABP3: heart-like fatty acid binding protein; 
BDNF: brain-derived neurotrophic factor; IGF-1: insulin-like growth factor-1; AOPP: advanced oxidation 
protein products; 8-OHdG: 8-hydroxy-2`-deoxyguanosine; MRI: magnetic resonance imaging; DAT: dopamine 
transporter; TCS: transcranial sonography; PET: positron emission tomography; SPECT: single photon emission 
computed tomography; WIS: wearable inertial sensors; and IMU: inertial measurement unit. *Includes species.
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overlapping between different protein aggregations and alterations of the midbrain-
striatal-cortical loop.
Dopamine transporter single photon emission tomography (DAT-SPECT) 
provides a semi-quantitative assessment of striatal dopaminergic deafferentation. 
This PD biomarker has a strong correlation between the amount of dopamine 
transporters in the striatum and the number of dopaminergic neurons in substantia 
nigra [51, 52].
The combined analysis of various imaging techniques will allow characterizing 
the baseline alterations related to the disease using DAT-SPECT, DTI, and MRI 
[53–55]. Functional MRI (fMRI) can show variation of connectivity functional 
network by detecting oxygenated hemoglobin and deoxyhemoglobin content in 
brain regions in PD patients [7, 56]. These changes can be present before motor 
symptoms, and can detect PD patients from normal individuals with a sensitivity of 
100% and a specificity of 89.5% [57, 58].
The combined blood and imaging biomarkers such as MR planimetric measure-
ments and NFL serum levels, provided accurate differentiation of PD versus multiple 
system atrophy (MSA) and progressive supranuclear palsy (PSP) patients. The com-
bined overall diagnostic yield was an accuracy of 83.7% (95% CI 69.8–90.8%) [59].
4.3 Digital data
Ecological and objective measurements made with wearable technology in 
patients’ homes are a reality. The analysis of gait domains in PD patients and its 
changes over time is a promising biomarker to track normal aging and the progres-
sion of the disease as the response to treatment [60].
Considering the functional interdependence of cognition and gait, objective 
analysis of gait and changes in certain gait domains may be a sensitive marker of the 
risk of cognitive impairment in patients with PD, observing greater asymmetry and 
variability in stride time, swing time, and posture compared to AD and Lewy body 
dementia (LBD) [61].
New technologies applied to the objective measurement of neurological 
symptoms or diseases will have to be subjected to an adequate scientific validation 
process.
5.  Clinical approach: the continuum of cognitive impairment and 
dementia in PD
It has been reported that PD patients may have normal cognition at the onset 
of the disease, although some patients present PD-MCI in the early stage of the 
disease and it is more frequent with the increment of years of the disease and older 
age [62]. In 2019, the International Parkinson and Movement Disorders Society 
(MDS) concluded that the diagnosis of level I PD-MCI is a risk factor to PDD while 
taking into account variables like age, sex, education, PD motor sign severity, and 
depression [63].
The most frequent alterations suggest that there are heterogeneous profiles that 
can be amnesic and non-amnesic. In general, it has been described that the most 
frequent deficits involve executive dysfunction, decreased attention, and visuo-
spatial dysfunction, as well as in global cognition. However, it is recognized that 
the PDD extends beyond dysexecutive syndrome to include deficits in recognition 
memory [64] and visual perception, as well as visual hallucinations and cognitive 
fluctuations [65]. These findings would indicate that cognitive problems could 
occur in patients in prodromal stages, which would be in line with the evidence 
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in favor of newly diagnosed or early stage patients already exhibiting deficits in 
cognition (Figure 2) [66].
The main cognitive domains that underlie the presence of PDD have been 
widely described, however, the compartmentalization is given to understand the 
complexity of clinical heterogeneity since neural networks interact and they overlap 
each other to finally define a cognitive function that is influenced by distributed 
individual actions [67]. Likewise, the existence of a “dual hypothesis” regarding 
the cognitive component has suggested that the PD-MCI could be a dopamine-
dependent profile closely related to the executive and working memory deficit, 
while the PDD could be a superordinal stage that it would imply the presence of 
other neurotransmission systems, which generate a picture of rapid progression 
exhibiting deficits in learned movements (apraxia), in recognition (agnosia), and in 
language (aphasia) in these patients [68].
Executive impairments in PD are due to the damage of connections between 
dorsolateral and ventrolateral frontal cortices with the globus pallidus internus 
and head of the caudate, as well as degeneration of mesocortical pathways with 
hypometabolism and atrophy prefrontal, insular, and cingulate cortices. Attention 
problems detected in the early stage of PD and PDD are related to frontal-parietal 
networks. Memory complaints are common even at the early stage of PD, although 
subjective memory complaints (SMC) at that point are more related with atten-
tional deficits. However, with the progression of PD-MCI to PDD dementia, 
memory impairments are similar to those found in AD, in relation to the difficulties 
with recalling and recognition, which are associated in PDD patients with medial 
temporal lobe atrophy. Further neuropsychological research is needed to make a 
proper association on this [67].
Visuospatial and visuoperceptive alterations are prominent of PDD, explained 
by deterioration in occipito-parietal connections (dorsal and ventral pathway 
related with spatial location and object recognition, respectively). Visual hallucina-
tions are a hallmark of PDD, and a relevant symptom which suggests the interrela-
tionship with LBD. Different networks are implicated in the visual hallucinations 
Figure 2. 
The continuum of cognitive impairment in PD patients. Figure 2 shows the relationship between genetic and 
epigenetic factors in the natural course of cognitive decline in Parkinson’s disease.
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such as middle occipital, inferior parietal lobule, nucleus basalis Meynert (NBM), 
and dysfunctional sleep-wake cycling with REM (rapid eye movement) sleep 
behavioral disorder (RBD) [67, 69].
Since it is well established, dopamine loss is the key of motor features, and 
the cornerstone of the PD treatment. However, acetylcholine, noradrenalin, and 
serotonin are responsible for the presence of non-motor symptoms, especially 
cognitive impairment. Loss of cholinergic neurons in NBM is found in 54–70% of 
PDD patients as well as 40% loss of neurons in brainstem cholinergic nucleus and 
the pedunculopontine nucleus [70]. The cholinergic diffused afference to cerebral 
cortex disrupts focused attention, memory encoding, and visual discrimination, 
and it is implicated in the generation of visual hallucinations [67, 69, 71].
Furthermore, noradrenalin deficit from locus coeruleus involving outputs to the 
thalamus, amygdala, and cortex contributes to damage in executive control, atten-
tion, and maintenance of arousal [71]. The role of the serotonin system has been 
less investigated in PDD than the neurotransmitters exposed above. It is known 
there is a reduction in the serotonergic transmission to caudate nucleus [69].
Neuroimaging studies have reported that frontal-subcortical and corti-
cal circuits could be involved in the development of PDD. The heterogeneous 
profile exhibits a decrease in dopaminergic frontal-striatal networks as well as a 
wide decrease in cholinergic cortical networks and a degeneration in the limbic-
paralimbic system [72]. On the other hand, studies that combine cognitive measures 
with neurophysiological markers have demonstrated that posterior and frontal-
executive cognitive task performance were associated with high risk of conversion 
to PDD [73].
The identification of PD-MCI is a critical point to management and potential 
clinical trials of pharmacological therapies. Moreover, the correct diagnosis of 
PD-MCI and PDD depends of the use of recommended cognitive tests for PD 
patients [74]. PD-MCI criteria include level I based on a screening evaluation to 
global cognition and level II based on comprehensive neuropsychogical assessment 
[75]. The MDS Task Force recommends three global screening scales for use when it 
is not possible to do a comprehensive neuropsychological testing; the scales are the 
following: Montreal Cognitive Assessment (MoCA), Mattis Dementia Rating Scale, 
and Parkinson’s Disease-Cognitive Rating Scale (PD-CRS) [76].
Because cognitive impairment in PD is beyond cognition, it is useful to ask to 
the patient and caregiver about subjective complaints, behavioral changes, and 
quality of life (Table 1). In addition, for the diagnosis of PDD, it is important to 
evaluate the functional independence in activity daily life (ADL) with question-
naires or scales recommended: Parkinson Disease Cognitive Functional Rating Scale 
(PD-CFRS), Functional assessment questionnaire, and the pill questionnaire [77].
Table 1 summarizes the affected neural networks and their effect on the 
patient’s cognitive domains with the neuropsychological tests recommended for 
their evaluation.
5.1 The cognitive impairment, non-motor symptoms, and motor subtypes
Interplay between motor and non-motor symptoms has been described with 
the objective to explore the relationship with different neurotransmitters systems 
related in the disease progression. Depression, anxiety, apathy, psychosis, fatigue, 
and sleep problems are common in PDD or even PD-MCI [78].
Also, the different clinical phenotypes of PD can relate the motor symptoms 
(MS) to non-motor symptoms (NMS). Factors that could contribute to the progres-
sion of the disease are also related to advanced age, the severity of motor symptoms, 
as well as the postural instability gait disorder (PIGD) subtype, the presence of 
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visual hallucinations, and associated cognitive deficits to the cortical-posterior pro-
file. Some NMS such as depression and anxiety have been related to specific motor 
subtypes, and it has been reported that poorer NMS profile are associated with 
PIGD subtype [79], besides history of falls and motor complications as an effect of 
pharmacological therapy [80].
Furthermore, PDD is more frequent among PIGD subtypes, and balance and 
gait disorders predict other non-motor symptoms (NMS) like hallucinations, 
urinary problems, and daytime sleepiness (12); whereas the alterations of attention 
and executive domain, which are related to frontostriatal deficits, could be consid-
ered a more stable profile [68]. Moreover, other studies have found that progression 
to PDD would also be associated with poor performance in executive tasks such as 
verbal fluency as well as other tests associated with cognitive flexibility, inhibition, 
and concept formation (commonly evaluated using the trail making test (TMT) 
part B, Wisconsin Card Sorting Test (WCST), and Stroop test) [81, 82].
The importance of detecting individual variables, as well as biomarkers for the 
heterogeneity of progression to PDD, then becomes useful information to contrib-
ute to the clarification of the pathophysiological mechanisms of cognitive impair-
ment in patients with PD [83].











• Stroop test; frontal assessment battery (FAB)
Working memory • Phonological verbal fluency
• Trail making test part B (TMT-B)
• WAIS-IV digit span
Noradrenergic network Orientation • WMS-IV orientation
Executive attention • Trail making test part A (TMT-A)
Cholinergic network Visuoperceptual 
deficits
• Judgment of line orientation (JLO)
Visual object and space perception (VOSP) 
battery
WAIS-IV block design
Memory deficits • Hopkins verbal learning test (HVLT); Rey 
auditory verbal learning test (RAVLT)
Wechsler memory scale (WMS-IV): logical 
memory, designs and visual reproduction Testt




Basal ganglia and 
dorsolateral prefrontal 
cortex network
Psychological status • Beck depression inventory (BDI-II)
Behavioral disturbance • Beck anxiety inventory (BAI-II)
• Frontal systems behavioral rating Scale 
(FrSB)
• Neuropsychiatric inventory questionnaire 
(NPI-Q )
Quality of life • Parkinson disease questionnaire-39 
(PDQ-39)
Table 1. 
Neural networks affected in PDD.
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In PD patients, the loss of dopaminergic neurons in the substantia nigra impacts 
the connections with the prefrontal cortex, which has suggested that it may attenu-
ate the cognitive component in these patients, as well as compromise the ability to 
cognitively compensate for the deficit in gait. Additionally, acetylcholine is related 
with attentional processes of the prefrontal cortex and has been strongly associated 
with a decrease in gait speed. In some patients with PD, this relationship may be 
exacerbated by freezing gait episodes, since it has been reported that this subgroup 
of patients has a worse performance in visuospatial skills tasks compared to those 
who have not, which could be related to a decrease in gray matter in posterior corti-
cal areas [84].
In studies carried out with different motor subtypes and patients with PD-MCI, 
it has been suggested that scores in the visuospatial domain are correlated with the 
stability factor, while the executive domain does not correlate with any factor, prob-
ably suggesting a more general role of executive functions. The processing of visual 
information is important during the planning and the control of locomotion in 
patients with PD. Additionally, low scores in stability factor was inversely associated 
with advanced stages on the Hoehn and Yahr scale, worse scores in MDS-UPDRS 
part III, suggesting that there is a specific relationship between motor progression, 
instability, and visuospatial alteration [85].
The relationship between the different aspects of balance and gait with the 
cognitive domains suggests that they are mediated by multiple neural pathways. 
Degeneration in the dopaminergic systems could contribute to cognitive deficits 
and the PIGD subtype, while degeneration within the cholinergic system has 
been proposed as a factor that contributes to cognitive and axial symptoms in PD 
patients. Hypofunction of the cholinergic system has been implicated in impaired 
executive functioning as well as a greater slowdown in gait speed in patients  
with PD [86].
6. Treatment
So far, there are no available treatments to cure or stop the progression of the 
synucleinopathies; hence, offering the best balance in the control of motor and non-
motor symptoms of the PD must be a main clinical objective. Due to the multisys-
temic and progressive nature of neurodegeneration, it is necessary to periodically 
update the inventory of cognitive, behavioral, and affective symptoms, alongside 
the motor and general health status, and also to determine the functional impact in 
daily life activities as well as on the social and working environment [87–89].
It is important to identify and strengthen the support network of caregivers to 
diagnose and give an appropriate support to the symptomatic complexity of each 
patient by a multidisciplinary team, which aims to improve their quality of life, 
reduce disability and health care costs, as well all risks mainly related to cognition 
and social behavior.
The adequate identification of high-risk clusters would allow the development 
of subtype specific therapeutic objectives. Moreover, recognizing the non-motor 
symptoms of high impact of quality of life such as mood disorders, sleep or eating 
disorders, and behavioral and social behaviors disorders could allow to define an 
appropriate clinical care [90].
Behind a specific symptom, there are brain areas or hypoactive or overactive 
functional associative networks with altered neurotransmitter systems such as 
dopaminergic, cholinergic, serotonergic, glutamatergic, or noradrenergic [26, 65]. 
For this reason, the analysis and functional neuroanatomical correlation on the 
temporal course of the disease as well as the cognitive profile is necessary for the 
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therapeutic selection and to reestablish, as far as possible or partially, the neuro-
chemical and functional balance (Figure 3).
Dopaminergic stimulation can cause some cognitive benefits on frontal execu-
tive functions, however, when the patient has motor complications, it could facili-
tate the appearance of some affective and cognitive fluctuations and could exert a 
negative effect on cognition [91].
Cholinergic denervation through different mechanisms affects cognition in 
patients with PD. For that reason, from cholinesterase inhibitors, Rivastigmine is 
the one with the best evidence of clinical efficacy and safety by improving some 
cognitive and neuropsychiatric domains. Such evidence is not similar for mild 
cognitive impairment, which is common in the disease [87, 92]. A possible applica-
tion of the cholinesterase inhibitors is to improve some gait domains and reduce the 
risk of fall, by increasing the cholinergic stimuli in the brain areas related to motor 
and cognitive control of gait [93].
Despite finding a glutamatergic hyperactivity that causes the progression of 
cognitive deficit in PD, memantine, an N-methyl-D-aspartate (NMDA) antagonist 
has shown a weak efficacy in improving cognitive functions [94].
The use of atomoxetine, a selective norepinephrine reuptake inhibitor (SNRI), 
was not effective for the treatment of depressive symptoms in PD, but was associ-
ated with improvement in global cognitive performance and daytime sleepiness; 
however, there is insufficient evidence on new indications for this drug [95].
Likewise, the use of transcranial direct-current stimulation (t-DCS) as well 
as repetitive transcranial magnetic stimulation (r-TMS) to improve the cognitive 
impairment has not reached enough evidence and recommendation in order to be 
recommended [96].
Both the interactions and the potential side effects can aggravate the cogni-
tive state and also produce psychosis, starting with the medicines used in the 
control of motor symptoms such as anticholinergics trihexyphenidyl, biperiden 
or benztropine, dopamine antagonist, and amantadine. It is important to monitor 
daily the interactions of medicines used in treatment of symptoms or concomitant 
chronic diseases and the potential interactions with the indicated medicines for 
Figure 3. 
Neurotransmitters systems related with motor and non-motor symptoms in PD. Figure 3 shows the interaction 
between neurotransmitters and PD symptoms with the estimated response in each category based on clinical 
experience.
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the control of neurological symptoms. Especially with benzodiazepines, anticho-
linergics/antimuscarinics used in gastrointestinal or bladder disorders, tricyclic 
antidepressants, or antipsychotic drugs, several observational studies have shown 
an association between exposure to anticholinergic drugs and the risk of cognitive 
impairment [97].
Rehabilitation as well as cognitive stimulation, whose objective is to develop 
strategies to improve or maintain functionality in daily activities, must be cus-
tomized according to the phenotype or the cognitive profile in each patient’s 
context [98, 99].
7. Conclusion
PDD is a rising, broad, and complex spectrum disorder with a high burden 
to patients and their caregivers. The prompt recognition of PD patients with red 
flags to progress to PDD is crucial to early enrollment in a multidisciplinary and 
therapeutic approach to diminish disease load. Nowadays, therapeutic options are 
limited. However, the advent of molecular, cellular, and technological advances 
creates a promissory future to specific treatment, allowing truly improvement in 
the patient’s and caregiver’s quality of life.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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